This report from The New England Journal of Medicine covers potential conflicts of interest between patient advocacy organizations that may be receiving funds from drug, biotech, and other medical companies. In the context of organization–industry relations, concerns have been raised that industry-supported patient-advocacy organizations have spoken out for access to drugs with questionable therapeutic benefit and remained silent on policy proposals, such as drug-pricing reforms, that might benefit their constituents.This study shows that among 104 of the largest U.S.-based patient-advocacy organizations, at least
83% received financial support from drug, device, and biotechnology companies, and at least
39% have a current or former industry executive on the governing board.